Chemotherapy for hormone-resistant prostate cancer: Where are we today?

Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC pat...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of urology 2007-01, Vol.23 (1), p.55-60
Main Authors: Buchler, Tomas, Harland, Stephen J
Format: Article
Language:English
Subjects:
Analysis
Cancer
Care and treatment
Chemotherapy
docetaxel
estramustine
Evaluation
Health aspects
hormone-refractory prostate cancer
mitoxantrone
Prognosis
Prostate cancer
Symposium
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC patients. Docetaxel is now considered the best available chemotherapy for prostate cancer progressing on first-line hormonal treatment. Other cytotoxics including mitoxantrone, anthracyclines, vinorelbin and vinblastine can alleviate symptoms and improve progression-free survival in HRPC without affecting overall survival. The survival benefit from chemotherapy seen in randomized studies has been small or nonexistent. Results of a recent trial suggest that the survival benefit may have been underestimated as a result of crossover from the less active to the active arm.
ISSN:0970-1591
1998-3824
DOI:10.4103/0970-1591.30269